Is it true that 9 out of 10 commercially insured patients have coverage for Moxeza?

The assertion that 9 out of 10 commercially insured patients have coverage for Moxeza is supported by data indicating that a significant majority of commercially insured individuals do indeed have access to this medication. Moxeza, an antibiotic eye drop used to treat bacterial conjunctivitis, is typically included in the formularies of many health insurance plans, reflecting its common use and the established medical necessity for treatment of eye infections.

Thus, the statistics align with the idea that a vast majority of commercially insured patients can receive coverage, making the statement accurate. Access to medications like Moxeza is often influenced by insurance policies that prioritize commonly prescribed treatments, further reinforcing the likelihood of widespread coverage among insured patients.